Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, is utilizing its RADR^® A.I. platform to enhance oncology drug development. The company will present at two investor conferences: the MicroCap Rodeo in Chicago, IL on October 12 at 10:00 a.m. CT, and the ThinkEquity Conference in New York, NY on October 26 at 10:30 a.m. ET. CEO Panna Sharma will lead both presentations, highlighting Lantern's focus on targeting therapies to patient-specific genomic profiles.

Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present preclinical data on its drug candidate LP-284 for mantle cell lymphoma (MCL) at the SOHO Tenth Annual Meeting from Sept. 28 to Oct. 1, 2022. LP-284 has demonstrated strong anti-tumor potency in MCL and other non-Hodgkin's lymphomas, particularly against Ibrutinib and Bortezomib-resistant cell lines. The company plans to submit an IND for LP-284 in Q1 2023 and launch a Phase 1 clinical trial in Q2 2023, aiming to capitalize on a $200 million annual market.

Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader webinar on September 22, 2022, at 12:00 p.m. ET. The webinar will address challenges in drug development for pediatric cancers and feature Dr. Peter Houghton, an expert from Greehey Children's Cancer Research Institute. He will discuss disparities in pediatric cancer research and present preliminary results for drug candidates LP-184 and LP-284. Registration details are available, with a replay on Lantern's website from September 23, 2022.

Lantern Pharma Inc. (NASDAQ: LTRN) announced the presentation of positive preclinical data for its drug candidate LP-184 targeting pancreatic cancer at the AACR Special Conference from Sept 13-16, 2022. The drug, which preferentially damages cancer cells with DDR gene mutations, demonstrated significant efficacy, achieving tumor growth inhibitions of 140% and 112% in mouse models. LP-184 has received Orphan Drug Designation from the FDA, with plans for IND submission in Q1 2023 and Phase 1 trials expected in Q2 2023.

Lantern Pharma Inc. (NASDAQ: LTRN) announces that CEO Panna Sharma will present at H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. Lantern Pharma utilizes its RADR^® AI platform to enhance oncology drug discovery, focusing on genomically targeted therapeutics. The company is currently developing four drug candidates across nine tumor targets. Details on registration and webcasting are provided for interested investors.

Lantern Pharma Inc. (NASDAQ:LTRN) will feature in an interview on The RedChip Money Report on Bloomberg TV on August 20 at 7 p.m. ET. CEO Panna Sharma will discuss the company's RADR® platform, which uses AI to optimize oncology drug development, aiming to reduce costs and enhance efficiency. Lantern is developing four drug candidates across nine tumor targets, including two in phase 2 trials. The interview is expected to highlight strategic collaborations with esteemed institutions like Johns Hopkins and Fox Chase Cancer Center.

Lantern Pharma (NASDAQ: LTRN) has launched the Phase 2 clinical trial, Harmonic™, for LP-300 targeting never smokers with advanced NSCLC, beginning patient enrollment in Q3 2022. The company plans to submit IND applications for LP-184 and LP-284 in early 2023, with two Phase 1 trials for LP-184 and one for LP-284 expected to commence thereafter. Lantern reported cash holdings of $62.2 million as of June 30, 2022, despite a net loss of approximately $4.5 million for the quarter. The RADR® platform surpassed 21 billion data points, enhancing its capabilities for future partnerships.

Lantern Pharma (NASDAQ: LTRN) will host a webcast on August 8, 2022, at 4:30 PM ET to discuss its Q2 financial results and future milestones. The company, focused on oncology drug discovery using its proprietary RADR® AI platform, is developing four drug candidates and an ADC program. Lantern aims to identify patients likely to respond to its therapies. Panna Sharma, CEO, will lead the discussion. A replay will be available on their investor relations website.

Lantern Pharma (NASDAQ: LTRN) has received FDA clearance to initiate the Harmonic™ trial, a Phase 2 clinical study for LP-300 in never smokers with advanced non-small cell lung cancer (NSCLC). The trial will enroll 90 patients and evaluate the drug in combination with chemotherapy, building on previous successes where LP-300 demonstrated a 91% overall survival and a 125% two-year survival for this demographic. Enrollment is expected to start in Q3 2022, targeting an estimated market of $1.5 to $2 billion for NSCLC.